Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | PharmSource report details factors driving bio/pharma development spendingIndustry intelligence leader offers insights into likely future demand for contract services
By: PharmSource PharmSource Information Services Inc. outlines this prediction – as well as justifications for it – in a new trend report titled CDMO and CRO Outlook: Robust Market Conditions Augur Growth, More M&A Activity Ahead. PharmSource is a premier leader in market intelligence for the global contract bio/pharma industry. “The bio/pharma industry’s need for new products, and the likelihood of the continued need for monetary stimulus in the macroeconomic environment, should provide a steady flow of new funding for an extended period,” said Jim Miller, PharmSource’ Miller cautions that there are risk factors that CDMO and CRO executives must be aware of, including facility and personnel challenges that may likely increase administrative costs as well as constrain capacity – and spur greater merger and acquisition activities. In developing the report, PharmSource’ PharmSource is the recognized authority of unbiased knowledge about the global bio/pharmaceutical contract services industry. The company’s proprietary publications, databases, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities. Since 1996, CMOs, CDMOs and CROs worldwide have looked to PharmSource for critical information delivered with timeliness and integrity. Learn more online. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|